The vaccine is a three-dose one administered intradermally using the painless PharmaJet, a needle-free system, Tropis, on Day 0, Day 28 and Day 56. Zydus Cadila on Wednesday announced that the company had started supplies of its Covid-19 vaccine, ZyCoV-D, to the Government of India. The group is also planning to make the vaccine available … Read more
Bharat Biotech thanked the DCGI, SEC and CDSCO for expediting the review process. (Representational image) The vaccine Subject Expert Committee (SEC) on Tuesday recommended granting of emergency use authorisation (EUA) for vaccine maker Bharat Biotech’s Covid-19-vaccine, Covaxin, for children in the 2-18 years age group. The SEC has recommended this to the Drugs Controller General … Read more
Covaxin phase 2/3 studies have been completed for 2 to 17 years age group population and immunogenicity and safety data have been submitted to the Drugs Controller General of India (DCGI) for further approvals. Even as India’s cumulative Covid-19 vaccination coverage exceeds 75.89 Crore, Covid-19 vaccination of children with comorbidities in the 12 to 17 … Read more
New Delhi: Drug firm Zydus Cadila on Monday said it has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market. The company said it has received approval from the US Food and Drug Administration (USFDA) for the drug in 11 mg and … Read more
According to Patel, Zydus Cadila had invested Rs 500 crore in developing the vaccine and in the manufacturing capacity with further investments expected as manufacturing capacity was being ramped up. The company had secured raw materials for next four to six months, Patel said. Zydus Cadila said on Saturday the company would start delivering the … Read more
A day after emergency use approval was granted to the Zydus Cadila Covid-19 vaccine, the pharma major has said that the price of the vaccine will be decided by next week. Managing Director of the pharma major Sharvil Patel was quoted as saying by ANI that there will be more clarity about the price of … Read more
An additional advantage with the Zydus Cadila vaccine is the fact that it is needle-free and thereby reduces the body pain and other side effects that are experienced with other vaccines. Covid-19 vaccine updates: In a crucial development in India’s fight against Coronavirus, Gujarat-based Zydus Cadila’s Covid-19 vaccine has got the emergency use approval for … Read more
The Phase 3 trials on more than 28,000 volunteers across 50 clinical sites, have shown an efficacy rate of 66.6%. That is lower than the efficacy levels of vaccines from Moderna and Pfizer-BioNTech that use mRNA technology. Zydus Cadila, which has sought the approval of DCGI for emergency use authorisation of its vaccine ZyCoV-D following … Read more
The drug, when given to Covid patients in the early stage, has shown significant clinical and virological improvement in moderate cases. (File Photo) Amid a continuous spike in the number of coronavirus cases in India, Zydus Cadila’s Virafin has been granted emergency use authorisation (EUA) for treatment of moderate cases of Covid-19 by the Drugs … Read more
Paul believes that even if Pfizer vaccine will come to India, it will be after a few months, and the health department will chalk out a different strategy. After the approval for rolling out Coronavirus vaccines in the UK, Pfizer’s entry is Indian market is much more of an academic interest. It is known that … Read more